{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:32:26Z","timestamp":1791563546946,"version":"4.3.4"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2021,2,1]]},"DOI":"10.1001\/jamacardio.2020.3151","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T02:58:19Z","timestamp":1597287499000},"page":"139","source":"Crossref","is-referenced-by-count":79,"title":["Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy"],"prefix":"10.1001","volume":"6","author":[{"given":"Prakash","family":"Deedwania","sequence":"first","affiliation":[{"name":"University of California School of Medicine, San Francisco, Fresno"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Scheen","sequence":"additional","affiliation":[{"name":"Department of Medicine, CHU Li\u00e8ge, Li\u00e8ge University, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolita","family":"Badariene","sequence":"additional","affiliation":[{"name":"Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando Lira","family":"Pineda","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narimon","family":"Honarpour","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Keech","sequence":"additional","affiliation":[{"name":"Sydney Medical School, NHMRC Clinical Trials Centre, University of Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Sever","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terje R.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Oslo University Hospital, Ullev\u00e5l and Medical Faculty, University of Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Deputy Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"hoi200053r1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jacc.2013.05.064","article-title":"Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010.","volume":"62","author":"Beltr\u00e1n-S\u00e1nchez","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"hoi200053r2","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1001\/jama.2015.4260","article-title":"Prevalence of the metabolic syndrome in the United States, 2003-2012.","volume":"313","author":"Aguilar","year":"2015","journal-title":"JAMA"},{"issue":"25","key":"hoi200053r3","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines.","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"hoi200053r4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"issue":"9539","key":"hoi200053r5","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","article-title":"Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.","volume":"368","author":"Deedwania","year":"2006","journal-title":"Lancet"},{"issue":"9716","key":"hoi200053r6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"hoi200053r7","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"hoi200053r8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jama.2015.1206","article-title":"Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus.","volume":"313","author":"Besseling","year":"2015","journal-title":"JAMA"},{"issue":"9965","key":"hoi200053r9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.","volume":"385","author":"Swerdlow","year":"2015","journal-title":"Lancet"},{"issue":"18","key":"hoi200053r10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"hoi200053r11","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"hoi200053r12","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome.","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"hoi200053r13","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in diabetes and the risk of development of diabetes: a prespecified analysis from the randomized controlled FOURIER Trial.","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"17","key":"hoi200053r14","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement.","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"16","key":"hoi200053r15","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"hoi200053r16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","article-title":"Rationale and design of the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk trial.","volume":"173","author":"Sabatine","year":"2016","journal-title":"Am Heart J"},{"issue":"9539","key":"hoi200053r18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0140-6736(06)69293-3","article-title":"Does the metabolic syndrome help to select patients requiring high statin dose?","volume":"368","author":"Scheen","year":"2006","journal-title":"Lancet"},{"issue":"29","key":"hoi200053r19","first-page":"2245","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.","volume":"38","author":"Landmesser","year":"2017","journal-title":"Eur Heart J"},{"issue":"39","key":"hoi200053r20","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1093\/eurheartj\/ehw292","article-title":"No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.","volume":"37","author":"Colhoun","year":"2016","journal-title":"Eur Heart J"},{"issue":"16","key":"hoi200053r21","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients.","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"10106","key":"hoi200053r22","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"hoi200053r17","unstructured":"US Department of Health and Human Services. Diagnosis of diabetes and prediabetes. Accessed June 30, 2020. https:\/\/cdn.ymaws.com\/www.chronicdisease.org\/resource\/resmgr\/NDPP\/diagnosis_508.pdf"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2769181\/jamacardiology_deedwania_2020_oi_200053_1612387615.45296.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T03:28:57Z","timestamp":1612841337000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2769181"}},"subtitle":["Secondary Analysis From the FOURIER Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2020.3151","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}